Search for media from: "Elke Vanderbeken"

Media

EAU 2024 - IMvigor011 - Surveillance - T. Powles… duration 6 minutes 41 seconds EAU 2024 - IMvigor011 - Surveillance - T. Powles… EAU 2024 - IMvigor011 - Surveillance - T. Powles (UK)	EAU 2024 - IMvigor011 - Surveillance - T. Powles (UK) EAU 2024 Clinical outcomes in patients with high-risk, post-cystectomy MIBC with persistent ctDNA-negative status on serial testing: surveillance analysis from the IMvigor011 study Thomas Powles MD… bladdercancer From Elke Vanderbeken 0 likes 23 plays 0 Content Declaration Keep for 3 Years COREMAP Content classification C4 No Language (In English) English
EAU 2024 - Discussion - J.Boormans, Rotterdam (NL) duration 6 minutes 14 seconds EAU 2024 - Discussion - J.Boormans, Rotterdam (NL) EAU 2024 - Discussion - J.Boormans, Rotterdam (NL)	EAU 2024 - Discussion - J.Boormans, Rotterdam (NL) EAU 2024 Prime Time for Adjuvant Treatment in Locally Advanced Bladder Cancer Joost L. Boormans, MD PhD bladder cancer From Elke Vanderbeken 0 likes 15 plays 0 Content Declaration Keep for 3 Years COREMAP Content classification C4 No Language (In English) English
Recurrence Read Training Overview of the process… duration 7 minutes 7 seconds Recurrence Read Training Overview of the process… Recurrence Read Training Overview of the process - Protocol v5 and above_final 17Apr2024	Recurrence Read Training Overview of the process - Protocol v5 and above_final 17Apr2024 In this short video a step-by-step guidance is being provided relating to how disease recurrence should be assessed and managed for the BO42843 IMvigor011 study. imaging disease recurrence guidance From Elke Vanderbeken 0 likes 19 plays 0 Content Declaration Keep for 3 Years COREMAP Content classification C4 No Language (In English) English